“Avelumab represents the most important pipeline for our company, the largest in the field of oncology: it deals with the fight against bladder cancer and we do it for patients, especially men, who need it. For us, the alliance with Pfizer means “Avelumab is a product that we have been able to develop for the benefit of patients and will also be able to demonstrate its superiority for their well-being.” This is how John Kirsten, President and CEO of Healthcare Merck Italia, at Adnkronos Health, on the day of the launch of the drug Avelumab, the result of the Merck-Pfizer alliance. The presentation of the therapy, already available in Italy after the Aifa ok for drug reimbursement, this morning on the occasion of the press conference “Let’s give the present time”, an event promoted by Merck and Pfizer.
“We have already worked in this area – emphasizes Kirsten – in the fight against cancer, mainly because they represent a long-term investment. The first time we developed a drug in oncology was 18 years ago and now avelumab bladder cancer.
“Our business, our company is mainly driven by research that is Merck’s main interest: in Italy in particular we have more than 16 centers that provided us with the data for this study and before obtaining the refund of our avelumab “The drug has already been given early access to the drug to 470 patients, simply on the basis of our desire to help them even before they have official AIFA registration,” he concluded.